Discovery of a Novel, Efficient, and Scalable Route to Bendamustine Hydrochloride: The API in Treanda

Synthesis and application of small molecules approved for the treatment of lymphoma

Lymphoma is a form of cancer that impacts the lymphatic system, which plays a crucial role in defending the body against infections and illnesses. It is characterized by the atypical proliferation of lymphocytes, a type of white blood cell, which can form tumors in the lymph nodes, bone marrow, spleen, etc. Lymphoma is usually treated using a combination of targeted therapy, chemotherapy, and radiation therapy. In recent years, there has been a growing interest in the development of new drugs to treat lymphoma, which has led to the discovery of several promising compounds. The primary targets for lymphoma treatment have been identified as Bruton's tyrosine kinase (BTK), phosphoinositide3-kinase (PI3K), histone deacetylase (HDAC), and DNA polymerase (POLA). This review aims to provide an overview of the clinical applications and synthesis of several notable drugs approved to treat lymphoma, to expedite the exploration of more potent novel medications for the management of lymphoma.

An efficient and facile synthesis of deuterium-labeled anticancer agent bendamustine hydrochloride

Bendamustine hydrochloride is an alkylating agent that was developed for the treatment of various human cancers. The stable isotope-labeled bendamustine was required to support clinic studies. An effective and operationally simple method for the synthesis of [D₆ ] bendamustine hydrochloride was developed using DCl as a catalyst and D₂ O as a deuterium source. Under the present condition, regioselectively deuterated bendamustine hydrochloride with high deuterium incorporation is achieved.

Continuous flow synthesis of a carbon-based molecular cage macrocycle via a three-fold homocoupling reaction

The facile synthesis of the cage molecule (C₁₁₀H₅₆Br₂) via a remarkable three-fold homo-coupling macrocyclization reaction using continuous flow methodology is reported.

Self-delivery nanoparticles from an amphiphilic covalent drug couple of irinotecan and bendamustine for cancer combination chemotherapy

We demonstrate an approach to prepare an anticancer drug self-delivery system from an amphiphilic covalent drug couple (Ir–Bd) for cancer combination chemotherapy.